Anti-TNF-α mAb (infliximab) is approved for the management of IBD, and anti oncostatin-M (GSK2330811) is currently being evaluated in clinical trials for controlling IBD [34,37,39,43,44]. The gene discussed is TNF; the disease is irritable bowel syndrome.